850335-27-2Relevant academic research and scientific papers
[6,6] FUSED BICYCLIC HDAC8 INHIBITORS
-
Paragraph 00242, (2019/08/15)
The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2', L, X, W, Y1,Y2,
Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
-
Page/Page column 35, (2010/11/28)
The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.
